Published in Retrovirology on March 09, 2009
Viruses, microRNAs, and host interactions. Annu Rev Microbiol (2010) 3.30
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology (2012) 1.62
NEAT1 long noncoding RNA and paraspeckle bodies modulate HIV-1 posttranscriptional expression. MBio (2013) 1.55
Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. J Virol (2011) 1.47
P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J Virol (2010) 1.40
XRN1 Is a Species-Specific Virus Restriction Factor in Yeasts. PLoS Pathog (2016) 1.38
Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs. J Virol (2014) 1.35
Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Front Microbiol (2013) 1.33
MicroRNAs and human retroviruses. Biochim Biophys Acta (2011) 1.23
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
MicroRNAs and HIV-1: complex interactions. J Biol Chem (2012) 1.13
Distinct functions of maternal and somatic Pat1 protein paralogs. RNA (2010) 1.06
Host genes associated with HIV-1 replication in lymphatic tissue. J Immunol (2010) 1.05
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
RNAi in the regulation of mammalian viral infections. BMC Biol (2012) 1.04
P-body components LSM1, GW182, DDX3, DDX6 and XRN1 are recruited to WNV replication sites and positively regulate viral replication. Virology (2012) 1.02
The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol (2011) 1.01
HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly. J Cell Biol (2012) 1.01
The DEAD-box RNA helicase DDX6 is required for efficient encapsidation of a retroviral genome. PLoS Pathog (2011) 1.00
Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology (2011) 0.99
HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol (2011) 0.97
The extent of sequence complementarity correlates with the potency of cellular miRNA-mediated restriction of HIV-1. Nucleic Acids Res (2012) 0.94
HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J Virol (2012) 0.94
Retroviral GAG proteins recruit AGO2 on viral RNAs without affecting RNA accumulation and translation. Nucleic Acids Res (2011) 0.93
Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry (2011) 0.92
A re-examination of global suppression of RNA interference by HIV-1. PLoS One (2011) 0.92
MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses (2012) 0.90
MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci (2011) 0.90
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi. PLoS One (2011) 0.88
Replication competent HIV-1 viruses that express intragenomic microRNA reveal discrete RNA-interference mechanisms that affect viral replication. Cell Biosci (2011) 0.87
Analysis of HIV-1 Gag protein interactions via biotin ligase tagging. J Virol (2015) 0.86
Function of a retrotransposon nucleocapsid protein. RNA Biol (2010) 0.86
Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol (2013) 0.86
Impact of cellular autophagy on viruses: Insights from hepatitis B virus and human retroviruses. J Biomed Sci (2012) 0.86
A proteomic study of TAR-RNA binding protein (TRBP)-associated factors. Cell Biosci (2011) 0.86
P bodies inhibit retrotransposition of endogenous intracisternal a particles. J Virol (2011) 0.85
APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J Virol (2011) 0.84
HIV-1 host interactions: integration of large-scale datasets. F1000 Biol Rep (2009) 0.82
Nuclear positional control of HIV transcription in 4D. Nucleus (2011) 0.80
HIV-1 suppressive sequences are modulated by Rev transport of unspliced RNA and are required for efficient HIV-1 production. PLoS One (2012) 0.79
Sequence requirements for localization and packaging of Ty3 retroelement RNA. Virus Res (2012) 0.79
Tombusvirus P19 RNA silencing suppressor (RSS) activity in mammalian cells correlates with charged amino acids that contribute to direct RNA-binding. Cell Biosci (2012) 0.78
Enterovirus71 (EV71) utilise host microRNAs to mediate host immune system enhancing survival during infection. PLoS One (2014) 0.77
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
Pathogens Use and Abuse MicroRNAs to Deceive the Immune System. Int J Mol Sci (2016) 0.77
APOBEC3 inhibits DEAD-END function to regulate microRNA activity. BMC Mol Biol (2013) 0.77
Who Regulates Whom? An Overview of RNA Granules and Viral Infections. Viruses (2016) 0.77
HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages. PLoS One (2015) 0.77
Human immunodeficiency virus Tat associates with a specific set of cellular RNAs. Retrovirology (2014) 0.76
Translational Control of the HIV Unspliced Genomic RNA. Viruses (2015) 0.76
Argonaute proteins regulate HIV-1 multiply spliced RNA and viral production in a Dicer independent manner. Nucleic Acids Res (2017) 0.75
Induced Packaging of Cellular MicroRNAs into HIV-1 Virions Can Inhibit Infectivity. MBio (2017) 0.75
Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. Virus Res (2016) 0.75
Movements of HIV-1 genomic RNA-APOBEC3F complexes and PKR reveal cytoplasmic and nuclear PKR defenses and HIV-1 evasion strategies. Virus Res (2015) 0.75
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science (2005) 13.84
Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell (2006) 12.73
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol (2008) 12.35
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature (2008) 10.71
mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev (2006) 8.78
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Antiviral immunity directed by small RNAs. Cell (2007) 8.09
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
A role for the P-body component GW182 in microRNA function. Nat Cell Biol (2005) 7.54
Widespread translational inhibition by plant miRNAs and siRNAs. Science (2008) 7.51
Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol (2006) 6.41
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. Nat Struct Mol Biol (2008) 5.57
Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol (2005) 5.52
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Argonaute proteins: mediators of RNA silencing. Mol Cell (2007) 5.16
A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing. RNA (2005) 5.15
Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 5.07
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
Molecular characterization of human Argonaute-containing ribonucleoprotein complexes and their bound target mRNAs. RNA (2008) 4.53
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity (2005) 3.70
Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe (2008) 3.14
Endogenous small interfering RNAs in animals. Nat Rev Mol Cell Biol (2008) 3.00
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Host factors exploited by retroviruses. Nat Rev Microbiol (2007) 2.79
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
Integration of the yeast retrotransposon Ty1 is targeted to regions upstream of genes transcribed by RNA polymerase III. Genes Dev (1996) 2.74
The transcriptional cycle of HIV-1 in real-time and live cells. J Cell Biol (2007) 2.69
The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog (2006) 2.61
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
P bodies, stress granules, and viral life cycles. Cell Host Microbe (2008) 2.23
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J (2006) 1.87
Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology (2008) 1.87
Virus-like particles of the Ty3 retrotransposon assemble in association with P-body components. RNA (2006) 1.77
Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology (2007) 1.77
A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. J Biol Chem (2001) 1.77
Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol (1992) 1.74
Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J (2006) 1.68
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
Latency: the hidden HIV-1 challenge. Retrovirology (2006) 1.59
Functional genomics reveals relationships between the retrovirus-like Ty1 element and its host Saccharomyces cerevisiae. Genetics (2003) 1.47
HIV-1 Tat RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1. Proc Natl Acad Sci U S A (2009) 1.39
Interactions between brome mosaic virus RNAs and cytoplasmic processing bodies. J Virol (2007) 1.14
The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13
Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology (2007) 1.12
A real-time view of the TAR:Tat:P-TEFb complex at HIV-1 transcription sites. Retrovirology (2007) 1.10
Factors controlling chromatin organization and nucleosome positioning for establishment and maintenance of HIV latency. Curr HIV Res (2008) 1.05
Keeping quiet: microRNAs in HIV-1 latency. Nat Med (2007) 1.00
Intragenic transcriptional cis-activation of the human immunodeficiency virus 1 does not result in allele-specific inhibition of the endogenous gene. Retrovirology (2008) 0.94
Are viral-encoded microRNAs mediating latent HIV-1 infection? DNA Cell Biol (2006) 0.93
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 5.07
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity (2005) 3.70
HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell (2010) 3.49
Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem (2002) 3.48
Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood (2004) 3.35
Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet (2004) 3.33
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Structural basis for budding by the ESCRT-III factor CHMP3. Dev Cell (2006) 3.18
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology (2012) 2.92
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep (2013) 2.56
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis (2003) 2.54
E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell (2006) 2.50
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature (2013) 2.34
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood (2013) 2.18
Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr (2004) 2.12
Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology (2005) 1.95
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J (2006) 1.87
Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology (2012) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol (2003) 1.82
Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. Bioessays (2006) 1.75
Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol (2007) 1.70
Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res (2009) 1.69
Post-transcriptional control of DGCR8 expression by the Microprocessor. RNA (2009) 1.67
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res (2008) 1.63
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. Mol Cell (2007) 1.56
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A (2007) 1.56
Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A (2011) 1.56
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis (2009) 1.49
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood (2011) 1.49
Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother (2003) 1.47
NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell (2012) 1.44
Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J Cell Sci (2003) 1.44
Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A (2002) 1.42
Monoclonal Gammopathy in HIV-1-Infected Patients: Factors Associated With Disappearance Under Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 1.40
Hypothermic Total Liquid Ventilation Is Highly Protective Through Cerebral Hemodynamic Preservation and Sepsis-Like Mitigation After Asphyxial Cardiac Arrest. Crit Care Med (2015) 1.39
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother (2009) 1.39
Simian foamy virus transmission from apes to humans, rural Cameroon. Emerg Infect Dis (2007) 1.35
Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic-silencing. Genome Res (2008) 1.28
Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J (2002) 1.27
Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J Gen Virol (2005) 1.27
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS (2007) 1.27
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS (2013) 1.26
Ubiquitination of human T-cell leukemia virus type 1 tax modulates its activity. J Virol (2004) 1.22
Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) (2004) 1.21
In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A (2010) 1.21
Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem (2002) 1.19
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis (2007) 1.17
p300 modulates ATF4 stability and transcriptional activity independently of its acetyltransferase domain. J Biol Chem (2005) 1.16
Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. Nat Struct Mol Biol (2011) 1.16
How SAMHD1 changes our view of viral restriction. Trends Immunol (2011) 1.15
Modes of transmission and genetic diversity of foamy viruses in a Macaca tonkeana colony. Retrovirology (2006) 1.14
Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. Blood (2013) 1.14
HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses. EMBO J (2005) 1.14
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr (2004) 1.13
Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology (2007) 1.12
Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog (2013) 1.10
Introduction of SARS in France, March-April, 2003. Emerg Infect Dis (2004) 1.10
Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood (2011) 1.09
Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol (2006) 1.09
siRNA, miRNA and HIV: promises and challenges. Cell Res (2005) 1.09
Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication. J Biol Chem (2002) 1.07
Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr (2008) 1.06
Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology (2007) 1.06
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS One (2010) 1.04
Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology (2013) 1.04
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04
Hyperthermia stimulates HIV-1 replication. PLoS Pathog (2012) 1.04
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol (2005) 1.03
Regulation of human SRY subcellular distribution by its acetylation/deacetylation. EMBO J (2004) 1.02